The global trade landscape has once again been rattled as the United States officially implemented sweeping new tariffs on a significant portion of imports from India. Effective August 27, 2025, these duties, which now stand at a steep 50%, signal a dramatic re-emergence of protectionist policies that many feared would
Duquesne's billionaire boss bid adieu to Wall Street's hottest artificial intelligence (AI) stock in favor of one of the cheapest pharmaceutical stocks on the planet.
Duquesne Family Office's billionaire chief dumped his fund's stake in Wall Street's artificial intelligence (AI) darling in favor of two reasonably cheap stocks that have taken off in recent years.
Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.
Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.
Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter.
